Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics (AVTX) with an Overweight rating and no price target Avalo is a clinical-stage biotech company focused on autoimmune diseases, the analyst tells investors in a research note. The firm says the company’s lead drug AVTX-009 is an IL-1N2 antibody currently in a Phase 2 trial for hidradenitis suppurativa with a readout expected in mid-2026.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics Reports Q2 2025 Financial Results
- Avalo Therapeutics: Promising Phase 2 Trial and Market Opportunities Drive Buy Rating
- Avalo Therapeutics reports Q2 EPS ($1.92), consensus ($1.48)
- Avalo Therapeutics management to meet virtually with Piper Sandler
- Avalo Therapeutics Highlights Potential of AVTX-009 in HS